Patents by Inventor Boris Masinovsky

Boris Masinovsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
    Patent number: 7449186
    Abstract: A therapeutic method of modulating the immune response, by administering to a patient an amount of IL-4 effective to promote peripheral blood lymphocyte adhesion to microvascular endothelial cells in lymphoid organs. The IL-4 is preferably coadministered with IL-1?. An improved method of screening a cell line for the production of a binding partner that binds with a cell adhesion molecule, by contacting the binding partner with IL4-activated and nonactivated microvascular endothelial cells, and selecting binding partners that bind to the IL4-activated microvascular endothelial cells but not to the nonactivated microvascular endothelial cells. The selected binding partners may thereafter be tested for the ability to block lymphocyte binding to cytokine-activated endothelial cells. The binding partners are preferably also characterized by binding to human VCAM-1 and to IL4- or TNF?-activated bone marrow stromal cells. A representative embodiment is mAb 6G10 produced by hybridoma ATTC No. HB10519.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: November 11, 2008
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Boris Masinovsky, William Michael Gallatin, Paul J. Simmons
  • Methods for using agents that bind to VCAM-1
    Patent number: 6123915
    Abstract: A therapeutic method of modulating the immune response, by administering to a patient an amount of IL-4 effective to promote peripheral blood lymphocyte adhesion to microvascular endothelial cells in lymphoid organs. The IL-4 is preferably coadministered with IL-1.beta..An improved method of screening a cell line for the production of a binding partner that binds with a cell adhesion molecule, by contacting the binding partner with IL4-activated and nonactivated microvascular endothelial cells, and selecting binding partners that bind to the IL4-activated microvascular endothelial cells but not to the nonactivated microvascular endothelial cells. The selected binding partners may thereafter be tested for the ability to block lymphocyte binding to cytokine-activated endothelial cells. The binding partners are preferably also characterized by binding to human VCAM-1 and to IL4- or TNF.alpha.-activated bone marrow stromal cells. A representative embodiment is mAb 6G10 produced by hybridoma ATTC No. HB 10519.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 26, 2000
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Boris Masinovsky, William Michael Gallatin, Paul J. Simmons
  • Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
    Patent number: 5827670
    Abstract: A therapeutic method of modulating the immune response, by administering to a patient an amount of IL-4 effective to promote peripheral blood lymphocyte adhesion to microvascular endothelial cells in lymphoid organs. The IL-4 is preferably coadministered with IL-1.beta..An improved method of screening a cell line for the production of a binding partner that binds with a cell adhesion molecule, by contacting the binding partner with IL4-activated and nonactivated microvascular endothelial cells, and selecting binding partners that bind to the IL4-activated microvascular endothelial cells but not to the nonactivated microvascular endothelial cells. The selected binding partners may thereafter be tested for the ability to block lymphocyte binding to cytokine-activated endothelial cells. The binding partners are preferably also characterized by binding to human VCAM-1 and to IL4- or TNF.alpha.-activated bone marrow stromal cells. A representative embodiment is mAb 6G10 produced by hybridoma ATTC No. HB 10519.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 27, 1998
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Boris Masinovsky, William Michael Gallatin, Paul J. Simmons
  • IL-4 and TNF induce mAb 6G10-recognized expression on bone marrow stromal cells
    Patent number: 5206345
    Abstract: An improved method of screening a cell line for the production of a binding partner that binds with a cell-surface molecule, by contacting the binding partner with IL4-activated and nonactivated human bone marrow stromal cells, and selecting binding partners that bind to the IL4-activated human bone marrow stromal cells but not to the nonactivated human bone marrow stromal cells. The selected binding partners may thereafter be tested for the ability to block CD34.sup.+ bone marrow cell binding to IL4-activated human bone marrow stromal cells. The binding partners are preferably also characterized by binding to human VCAM-1. A representative embodiment is mAb 6G10 produced by hybridoma ATTC No. HB 10519.
    Type: Grant
    Filed: August 2, 1990
    Date of Patent: April 27, 1993
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Boris Masinovsky, William M. Gallatin, Paul J. Simmons